+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Von Willebrand Disease Treatment Market by Product Type, Treatment Type, End User, Distribution Channel, Severity - Global Forecast to 2030- Product Image
Von Willebrand Disease Treatment Market by Product Type, Treatment Type, End User, Distribution Channel, Severity - Global Forecast to 2030- Product Image
Sale

Von Willebrand Disease Treatment Market by Product Type, Treatment Type, End User, Distribution Channel, Severity - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715686
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Von Willebrand Disease Treatment Market grew from USD 718.76 million in 2024 to USD 804.82 million in 2025. It is expected to continue growing at a CAGR of 11.53%, reaching USD 1.38 billion by 2030.

Setting the Stage for Innovations in Von Willebrand Disease Treatment

Von Willebrand disease stands as the most common inherited bleeding disorder, affecting millions worldwide with symptoms ranging from mild bruising to life-threatening hemorrhages. As the therapeutic landscape evolves, stakeholders require an authoritative overview of treatment modalities, regulatory shifts, and patient access dynamics. This executive summary delivers a concise yet comprehensive introduction to emerging interventions, clinical practice patterns, and pharmaceutical innovations. By contextualizing recent developments and identifying critical market drivers, the report equips decision-makers with the clarity needed to navigate a complex environment. The following sections will shed light on transformational trends, policy influences, segmentation nuances, and regional variations, all culminating in strategic recommendations. Readers will gain a foundational understanding of the current state of von Willebrand disease treatment and the roadmap for future growth and investment.

Emerging Paradigms Redefining von Willebrand Disease Management

A rapid convergence of biotechnological breakthroughs and personalized medicine has redefined von Willebrand disease management. Recombinant von Willebrand factor concentrates have gained traction, reducing reliance on plasma-derived products and mitigating pathogen transmission risks. Meanwhile, innovative delivery formats for desmopressin, including intranasal sprays and intravenous formulations, have enhanced patient convenience and adherence. Antifibrinolytic therapies such as aminocaproic acid and tranexamic acid have been optimized for acute and perioperative settings, offering targeted hemostasis with reduced systemic exposure. In parallel, digital health platforms now enable remote monitoring of bleeding episodes and prophylactic regimens, fostering data-driven care and real-time adjustments. These developments, when combined with robust clinical guidelines and real-world evidence, are reshaping therapeutic paradigms and expediting the adoption of preventative strategies. As a result, the standard of care is shifting from reactive intervention toward proactive disease control, paving the way for improved patient outcomes and sustainable healthcare delivery.

Assessing the 2025 US Tariff Implications on Von Willebrand Therapies

The introduction of new tariffs on imported biologics and active pharmaceutical ingredients in 2025 has prompted stakeholders to reassess supply chain configurations and cost structures. Manufacturers face elevated production expenses, driven by duties on key reagents used in recombinant von Willebrand factor manufacturing. Consequently, pricing pressures may emerge, potentially translating into higher treatment costs for healthcare providers and patients. To mitigate these challenges, some producers are exploring domestic manufacturing partnerships or strategic inventory positioning near key demand centers. Insurers and hospital systems are negotiating value-based contracts that tie reimbursement to clinical outcomes, while patient advocacy groups lobby for tariff exemptions on essential hemostatic agents. Although initial adjustments have introduced complexity in procurement cycles, a collaborative response among regulators, payers, and manufacturers is fostering adaptive solutions. In the long run, the tariff landscape is likely to incentivize innovation in local production and distribution, driving resilience against external shocks.

Unpacking Market Drivers Through In-Depth Treatment and Distribution Segmentation

An in-depth examination of market segments reveals diverse growth drivers across product type, treatment type, end user, distribution channel, and disease severity. Research on desmopressin encompasses both intranasal sprays for self-administration and intravenous formulations used in specialized settings, while hemostatic agents emphasize antifibrinolytic compounds such as aminocaproic acid and tranexamic acid. Replacement therapies span plasma-derived von Willebrand factor concentrates and next-generation recombinant concentrates that promise higher purity and consistent potency. When viewed through the lens of treatment modality, on-demand interventions address acute bleeding and preprocedural management, whereas prophylactic strategies range from continuous infusion regimens to intermittent dose schedules tailored to patient lifestyle. The end-user landscape extends from outpatient and specialty clinics to dedicated hemophilia treatment centers and hospital networks, including both private and public institutions. Distribution pathways vary across hospital pharmacies, online platforms, and retail establishments, with chain and independent pharmacies playing complementary roles. Disease severity stratification captures patients with Type 1 presentations, a spectrum of Type 2 subtypes including 2A, 2B, 2M, and 2N, and those with severe Type 3 deficiency. Understanding the interplay among these dimensions illuminates patient needs, resource allocation, and innovation priorities.

Navigating Regional Dynamics Shaping Global Von Willebrand Disease Care

Regional analysis highlights distinct competitive dynamics and growth opportunities across the Americas, Europe Middle East & Africa, and Asia-Pacific territories. In the Americas, robust healthcare infrastructure and high per-capita expenditure support rapid uptake of recombinant therapies and novel delivery devices, although reimbursement scrutiny demands clear value demonstration. The Europe Middle East & Africa region exhibits heterogeneous market access, with Western Europe advancing prophylactic adoption while emerging markets emphasize cost-effective plasma-derived options under evolving regulatory frameworks. Meanwhile, Asia-Pacific presents a dual narrative: established markets in Japan and Australia lead in biopharmaceutical innovation, whereas developing countries in Southeast Asia pursue generic alternatives and public-private initiatives to expand treatment availability. Cross-border collaborations and local manufacturing incentives are reshaping competitive dynamics, as stakeholders seek to address diverse patient populations and regulatory environments. Tailored strategies that reflect regional payer models, clinician preferences, and patient advocacy efforts will determine future success in each market cluster.

Profiling Leading Innovators Driving Advances in Von Willebrand Therapies

Several key players are driving advances in von Willebrand disease treatments through strategic investments, pipeline diversification, and collaborative partnerships. A leading biopharmaceutical organization has leveraged its expertise in plasma protein fractionation to expand its recombinant von Willebrand factor portfolio, reinforcing supply reliability and enhancing product consistency. Another global company has focused on pegylated formulations and extended-release desmopressin to improve patient compliance and reduce infusion frequency. A specialty firm has carved a niche in antifibrinolytic therapies, optimizing aminocaproic acid and tranexamic acid dosing algorithms for acute and surgical settings. Additional competitors have entered the space with novel gene therapy candidates targeting durable expression of functional von Willebrand factor, forging alliances with academic centers to accelerate clinical milestones. Emerging biotechnology ventures are harnessing synthetic biology platforms to engineer next-generation concentrates with tailored glycosylation profiles. Across the board, these organizations emphasize evidence generation, real-world data collection, and engagement with patient advocacy networks to validate therapeutic value and support differentiated positioning.

Strategic Imperatives for Stakeholders in Von Willebrand Disease Treatment

Industry leaders should prioritize investments in recombinant and gene-based therapies that promise higher safety margins and consistent supply, while maintaining strategic alliances with plasma producers to manage transitional demand. Strengthening local manufacturing capabilities and forging public-private partnerships can mitigate tariff impacts and enhance market resilience. To drive adoption, commercial teams must craft differentiated value propositions that highlight real-world outcomes and cost-effectiveness, partnering with payers to develop outcome-linked reimbursement models. Expanding digital patient engagement platforms will bolster adherence tracking and data collection, enriching clinical insights and supporting continuous therapy optimization. In addition, companies should tailor market access strategies to regional payer frameworks and clinician workflow preferences, deploying targeted educational initiatives in outpatient clinics, hemophilia treatment centers, and hospital settings. By integrating patient severity profiles into predictive modeling, stakeholders can align supply chain planning with fluctuating demand across Type 1, Type 2 subtypes, and Type 3 cohorts. Embracing these strategic imperatives will unlock sustainable growth and cement leadership in the evolving von Willebrand disease treatment arena.

Robust Methodological Framework Underpinning Market Analysis

This analysis draws from a rigorous, multi-tiered research framework combining primary and secondary intelligence sources. The methodological approach included in-depth interviews with hematology specialists, payers, and patient representatives, complemented by confidential surveys of clinical trial investigators. Secondary research encompassed peer-reviewed publications, regulatory filings, and company disclosures, ensuring comprehensive coverage of therapeutic developments and policy shifts. Data validation employed cross-referencing among proprietary databases and public domain insights, while quantitative analyses leveraged segmentation across product type, treatment paradigm, end-user setting, distribution channel, and disease severity. Regional market dynamics were mapped through granular assessments of reimbursement structures, clinician adoption rates, and competitive benchmarking. Quality assurance protocols governed each stage of data collection and interpretation, reinforcing the credibility and reliability of conclusions. This robust methodology underpins the strategic recommendations and visuals throughout the full report.

Converging Insights Inform the Future of Von Willebrand Disease Treatments

The convergence of innovative delivery mechanisms, recombinant and gene-based platforms, and patient-centric digital tools is reshaping the von Willebrand disease treatment landscape. While tariff adjustments and regional disparities present short-term challenges, they also catalyze supply chain optimization and local manufacturing initiatives. Segmentation insights reveal nuanced opportunities across product modalities, treatment regimens, care settings, and patient severity groups, guiding resource allocation and commercial focus. Regional analysis underscores the importance of adaptive market access tactics tailored to distinct healthcare systems. Leading companies demonstrate that a commitment to evidence generation, strategic partnerships, and technological advancement yields competitive advantage. The recommendations outlined herein provide a blueprint for industry leaders to anticipate market shifts, engage stakeholders effectively, and secure long-term growth. Altogether, the insights presented in this executive summary inform a cohesive strategy for navigating the complexities of future von Willebrand disease therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Desmopressin
      • Intranasal
      • Intravenous
    • Hemostatic Agents
      • Antifibrinolytics
        • Aminocaproic Acid
        • Tranexamic Acid
    • Replacement Therapies
      • Plasma Derived Vwf Concentrates
      • Recombinant Vwf Concentrates
  • Treatment Type
    • On Demand
      • Acute Treatment
      • Preprocedural Treatment
    • Prophylaxis
      • Continuous Prophylaxis
      • Intermittent Prophylaxis
  • End User
    • Clinics
      • Outpatient Clinics
      • Specialty Clinics
    • Hemophilia Treatment Centers
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacies
      • Independent Pharmacies
  • Severity
    • Type 1
    • Type 2
      • Type 2A
      • Type 2B
      • Type 2M
      • Type 2N
    • Type 3
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Grifols, S.A.
  • Laboratoire Français du Fractionnement et des Biotechnologies
  • Kedrion S.p.A.
  • Bio Products Laboratory Limited
  • Biotest AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Von Willebrand Disease Treatment Market, by Product Type
8.1. Introduction
8.2. Desmopressin
8.2.1. Intranasal
8.2.2. Intravenous
8.3. Hemostatic Agents
8.3.1. Antifibrinolytics
8.3.1.1. Aminocaproic Acid
8.3.1.2. Tranexamic Acid
8.4. Replacement Therapies
8.4.1. Plasma Derived Vwf Concentrates
8.4.2. Recombinant Vwf Concentrates
9. Von Willebrand Disease Treatment Market, by Treatment Type
9.1. Introduction
9.2. On Demand
9.2.1. Acute Treatment
9.2.2. Preprocedural Treatment
9.3. Prophylaxis
9.3.1. Continuous Prophylaxis
9.3.2. Intermittent Prophylaxis
10. Von Willebrand Disease Treatment Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Specialty Clinics
10.3. Hemophilia Treatment Centers
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Von Willebrand Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacies
11.4.2. Independent Pharmacies
12. Von Willebrand Disease Treatment Market, by Severity
12.1. Introduction
12.2. Type 1
12.3. Type 2
12.3.1. Type 2A
12.3.2. Type 2B
12.3.3. Type 2M
12.3.4. Type 2N
12.4. Type 3
13. Americas Von Willebrand Disease Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Von Willebrand Disease Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Von Willebrand Disease Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Octapharma AG
16.3.4. Grifols, S.A.
16.3.5. Laboratoire Français du Fractionnement et des Biotechnologies
16.3.6. Kedrion S.p.A.
16.3.7. Bio Products Laboratory Limited
16.3.8. Biotest AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. VON WILLEBRAND DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 90. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 92. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 95. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 96. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 98. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 102. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 103. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 105. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 110. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 116. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 117. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 179. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 181. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 186. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 193. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 194. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 196. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 201. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 204. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 208. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 224. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 226. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 227. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 228. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 231. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 232. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 237. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 238. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 239. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 241. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 242. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 243. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 246. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 252. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 253. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 298. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2030 (USD MILLION)
TABLE 299. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT T

Companies Mentioned

The companies profiled in this Von Willebrand Disease Treatment market report include:
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Grifols, S.A.
  • Laboratoire Français du Fractionnement et des Biotechnologies
  • Kedrion S.p.A.
  • Bio Products Laboratory Limited
  • Biotest AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 804.82 Million
Forecasted Market Value ( USD ) by 2030 $ 1380 Million
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Von Willebrand's Disease - Pipeline Insight, 2025 - Product Image

Von Willebrand's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Textbook of Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 2 - Product Image

Textbook of Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 2

  • Book
  • 304 Pages
Bleeding Disorder Diagnostics Market by Product Type, Technology, End User, Application, Disease Type - Global Forecast to 2030 - Product Image

Bleeding Disorder Diagnostics Market by Product Type, Technology, End User, Application, Disease Type - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1 - Product Image

Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1

  • Book
  • 268 Pages
Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032 - Product Image

Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From

About the Von Willebrand Disease Drug Market

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF). The von Willebrand Disease Drug market is a subset of the Hematological Drugs market, which includes drugs used to treat blood-related disorders. VWD drugs are used to treat the symptoms of VWD, such as excessive bleeding, and to prevent bleeding episodes. These drugs are typically administered intravenously or subcutaneously, and may include desmopressin, antifibrinolytics, and recombinant VWF. The Von Willebrand Disease Drug market is highly competitive, with several major players. These include Shire, Pfizer, Novo Nordisk, CSL Behring, and Bayer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.